Distinguishing Between Off-Label Guidelines for Device vs. Pharmaceutical Companies
July 14, 2010
David Rosen will present, “Distinguishing Between Off-Label Guidelines for Device vs. Pharmaceutical Companies” at the ACI 7th National Forum on Off-Label Communications, July 14-15, 2010 at the Union League, in Philadelphia.
Speakers will cover compliance strategies with FDA off-label promotion guidelines, training physicians on the use of medical devices, and learning from device manufacturers’ litigation. Thomas Lynch, Senior Corporate Counsel at Boston Scientific will join Mr. Rosen as a speaker.
More information can be found on ACI’s Web site.
People
Related Insights
June 10, 2025
Foley Viewpoints
EPA to Approve Texas use of CO2 Sequestration Wells
Today, the EPA took an important step in allowing Texas to issue permits for Class VI wells within the state. Class VI wells are used for…
June 10, 2025
Foley Viewpoints
Supreme Court Rejects Minimum Contacts Requirement to Subject Foreign States to Suits in the U.S. Under FSIA
On June 5, 2025, in a unanimous decision authored by Justice Alito, the United States Supreme Court held that the Foreign Sovereign Immunities Act of 1976 (FSIA), 28 U.S.C. §§1330, 1602 et seq., does not require a plaintiff to prove a foreign state has made “minimum contacts” with the United States sufficient to satisfy the personal jurisdiction test set forth in International Shoe Co. v. Washington, 326 U.S. 310, 316 (1945).
June 10, 2025
Foley Ignite
Investor Insights: An Overview of PitchBook’s H1 2025 VC Tech Survey
Having done a deep dive into PitchBook’s H1 2025 VC Tech Survey, not to mention living and breathing the state of venture with my clients who are in market for capital, I wanted to share my thoughts about how investors appear to be recalibrating their approach to technology startups.